Lundbeck gains new chief executive from Novo Nordisk
pharmafile | May 6, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Kåre Schultz, Lundbeck, Novo Nordisk, Rebien Sorensen
Danish pharma giant Lundbeck has appointed Kåre Schultz as its new president and chief executive.
Schultz (pictured) will take up his new position shortly and joins from Novo Nordisk where he served as its president and chief operating officer.
He replaces the vacant spot left by Ulf Wiinberg who resigned from his post last year following a beach of its rules relating to shares.
“It is a great pleasure to announce that Kåre Schultz will join Lundbeck as president and chief executive. With his unique experience from an impressive career in the pharmaceutical industry, Kåre Schultz has all the qualifications to handle the challenges Lundbeck faces,” says Håkan Björklund, Lundbeck’s chairman.
Schultz has been the president and COO of Novo since January last year, having originally joined Lundbeck’s fellow Danish firm back in 1989. He is also a chairman at Royal Unibrew and a member of the board of LEGO, both in Denmark.
He left Novo Nordisk just recently when he learned that its current CEO Rebien Sorensen – who was expected to step down shortly – would be staying on in the role until 2019, as Schultz had been tipped to replace Sorensen and clearly hoped this would have happened sooner.
“Lundbeck stands out in the industry as a company focussed on brain diseases. I’m motivated and inspired by Lundbeck’s vision and excited to bring my business background to lead Lundbeck to the next phase of its development,” says Schultz.
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
